Dyne Therapeutics

DYNE THERAPEUTICS INC

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

stock traders shutter

Analyst Color

Biotech

News

Health Care

Analyst Ratings

General

JP Morgan analysts question Dyne Therapeutics&#39; strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor concerns over data updates.

JPMorgan Seeks Clarity On Dyne Therapeutics&#39; DYNE-101 Expansion, Regulatory Path

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Equities

Initiation

Trading Ideas

BMO Capital Markets initiates coverage on Dyne Therapeutics with an Outperform rating, an $84 target, and a projected $4.3 billion peak sales for DYNE-101.

Dyne Therapeutics&#39; $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

Pharmaceutics,Laboratory:,Pipette,Dropping,Yellow,Liquid,Into,Test,Tubes,,Medical

Movers

Dyne Therapeutics&#39; DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated Approval by 2026.

Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

Dyne Therapeutics Inc

DYNASTAR HOLDINGS INC by Dynastar Holdings, Inc.

Dynastar Holdings Inc

Dye & Durham Ltd

DynTek, Inc. Com

iShares U.S. Equity Factor Rotation Active ETF

IDX Dynamic Innovation ETF

DynaResource Inc

Dynatronics Corp

Dynamix Corporation - Class A Ordinary Share

Dynamix Corp

Press Releases

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

Earnings

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Management

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Ardelyx

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

89bio

Geron

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Disc Medicine

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

MiMedx Group

Mesoblast Limited - American Depositary Shares

Mesoblast

MannKind

Novavax

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Comments

Dyne Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga